Discontinuation (procedure)

AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

1 month ago talkbio0Tagged ADT, androgen-deprivation therapy, AstraZeneca, CAPItello-280, capivasertib, Clinical Trials, Discontinuation (procedure), docetaxel, Failure (biologic function), Inhibitor, Metastatic castration-resistant prostate cancer, oncology setback, Phase 3 Clinical Trials, Progression-Free Survival, Proto-Oncogene Proteins c-akt, Radiographic, Survival, Truqap

Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival

Cassava Sciences Discontinues Alzheimer’s Program After Simufilam Fails Second Phase 3 Trial

2 months ago talkbio0Tagged Alzheimer 's disease, Discontinuation (procedure), Drug Development, Failure (biologic function), Manihot esculenta, Phase 3 trial, Simufilam

Cassava Sciences, simufilam, Alzheimer’s disease, Phase 3 trial failure, drug development discontinuation

Lava cuts jobs by 30% after key drug discontinued

3 months ago talkbio0Tagged cash runway, Discontinuation (procedure), LAVA, LAVA-1266, mCRPC, restructuring, strategic alternatives

LAVA Therapeutics, restructuring, workforce reduction, LAVA-1207, discontinuation, mCRPC, LAVA-1266, strategic alternatives, cash runway

Pfizer Discontinues Hemophilia B Gene Therapy Beqvez, Exits Gene Therapy Field

3 months ago talkbio0Tagged Beqvez, Discontinuation (procedure), Exit, gene therapy, Hemophilia B, Pfizer, portfolio

Pfizer, Beqvez, hemophilia B, gene therapy, discontinuation, portfolio exit

Septerna Halts Phase 1 Trial of SEP-786 Due to Unexpected Bilirubin Elevations

4 months ago talkbio0Tagged Agonist, Bilirubin, Clinical Trials, Discontinuation (procedure), Hypoparathyroidism, PTH1R gene, SEP-786, Septerna

Septerna, SEP-786, clinical trial discontinuation, hypoparathyroidism, bilirubin elevation, PTH1R agonist, biotech setback

Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

4 months ago talkbio0Tagged Arenaria, Biological Factors, clinical program, Discontinuation (procedure), Financial cost, Industry, Lymphocytes, Tumor-Infiltrating, Manufacturing, strategic alternatives, TIDAL-01

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges